/
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders.
21.64% operating margin is above average. ROIC at 11.52%.
Revenue grew 21.4%, still solid. Margins contracted 2.6pp, which offsets some of the top-line progress.
ROIC dropped from 15.19% to 11.52%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
$3.10B
▲ +21.4% YoY
Net Income (TTM)
$669M
▲ +40.2% YoY
Op. Margin
25.43%
▼ -2.6pp YoY
ROIC
14.58%
▼ -3.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$831M
▲ +34.4% YoY
Op. Cash Flow (TTM)
$864M
▲ +31.5% YoY
Net Debt
-$853M
Net Cash Position
Cash & Equiv.
$1.32B
5Y CAGR: +22.3%
5Y CAGR: +28.0%
Continue Research